Jimin's innovative polycystic kidney disease innovative drug was approved by the FDA for clinical trials
Jimin Trust Group recently announced that its subsidiary Shanghai Jiyu Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai Jiyu") has been approved by the US FDA for the innovative drug JMKX003142 oral tablet new drug application (IND), agreeing to carry out clinical trials of the drug in patients with polycystic kidney disease indications.

Autosomal dominant polycystic kidney (ADPKD) is often found in middle adolescence, with an incidence of about 1/400 – 1/1000, and is expected to have 12.5 million patients worldwide and 1.5 million patients in China. [1] Due to the lack of targeted therapeutic drugs, about 40-50% of these patients will develop end-stage renal disease and have to undergo dialysis or kidney transplantation, which puts a greater burden on the patient's family and society.
JMKX003142, independently developed by Shanghai Jiyu Small Molecule Innovation Institute, is the first innovative drug research and development project for polycystic kidney disease in China, with the world's best (BIC) potential. Preclinical animal efficacy studies and safety evaluation showed that JMKX003142 can inhibit the proliferation of LLC-PK1 cells in a dose-dependent manner and inhibit the volume of human ADPKD renal vesicle cells, avoiding the side effects caused by the Hook effect of other drugs (high concentration promotes proliferation), and has differentiated global competitiveness.
It is understood that JMKX003142 will carry out clinical trials in many places in the near future. It is hoped that in the near future, the drug will become a boon for the majority of ADPKD patients and change the situation in which no drug is available.
2026-10-30
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
24th Pharma Asia Kicks Off in Karachi, Pakistan’s Largest Pharmaceutical Industry Event
-
24th Pharma Asia International Exhibition & Conferences to Open in Karachi, Pakistan
-
GLP-1 API Route to U.S. Abruptly Narrows: FDA Heavily Penalizes U.S. Compounding Pharmacy and Bypasses Warning Letter to Ban Chinese Factory
-
China's Ibuprofen Export Performance, First Half of 2026
-
Germany Passes Healthcare Reform, Multinational Drugmakers Face 15.5% Mandatory Discount
-
The relationship between Digital Transformation and Work- Life Balance in the Egyptian Pharmaceutical Industry
-
What Does the Future Hold for the Anti-Obesity Drug Market in 2024?
-
Hengrui entered the top 20 for the first time. How big is the gap between Chinese and American pharmaceutical companies?
-
The State Food and Drug Administration accepted the marketing application of Ditze Pharma suvortinib
-
Another giant may be broken up
Recommend Reading
-
EFSA Reviews Clodinafop Risk
-
China NMPA Issues Priority Review Pathway for Four Categories of Chemical Active Pharmaceutical Ingredients, Effective August 1, 2026
-
U.S. Imposes 12.5% Additional Tariff! Nutritional Ingredients Including Creatine, Taurine, and Glucosamine Included in New Section 301 Tariff List
-
India Approves ₹30.3 Billion Chemical-Park Scheme to Build Three Mega Industrial Hubs
-
EFSA’s Updated Food-Additive Application Guidance Takes Effect
-
Multiple Factors Interwoven, Short-Term Fluctuations in Polyethylene
-
Construction Starts Decline, Isocyanide Prices Surge After the Holiday
-
This Week, PET Bottle Chip Spot and Futures Prices Move Downward in Tandem in China
-
Ethanol Market Prices Remain Weak and Consolidate
-
High-level Fluctuations, Weakening Momentum for Increase: May 2026 Natural Rubber Market Analysis in China